Search Results for “EC” – Page 575

Leaf Healthcare touts reduced pressure injuries in Leaf wearable sensor study

Patient monitoring system developer Leaf Healthcare today released results from a study exploring the ability of its Leaf wearable patient sensor to prevent pressure injuries on acutely ill adults, touting that patients were 73% less likely to develop such injuries when monitored with the device.

Source: Mass Device
606
January 24, 2018

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Sandoz, a Novartis division and the global leader in biosimilars, announced a global partnership with Asia’s premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars in immunology and oncology for patients worldwide.

Source: Sandoz
582
January 23, 2018

biosimilars immunology Market Views oncology

Merck KGaA taps UK cancer research organizations to feed pipeline

After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.

Source: Endpts
554
January 23, 2018

Bavencio cancer inhibitor Market Views

Biosimilar Avastin wins EU approval

European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...

Source: Pharmatimes
560
January 23, 2018

Avastin Mvasi New Approvals Roche

GSK, Pfizer lead in new global Twitter pharma influencer ranking

Tweeting to the top, GlaxoSmithKline and Pfizer tied for the No. 1 spot in the inaugural ranking of global pharma influencers by Owen Health. The U.K.-based healthcare marketing agency evaluated 22 pharma companies on authority, reach, activity, engagement and influence to rate the most and least adept when it comes to Twitter.

Source: fiercepharma
620
January 23, 2018

global pharma influencers GSK Pfizer

Diagnostic Products of the Future

Panelists at the recent J.P. Morgan Healthcare Conference in San Francisco, CA were charged with separating the hype from the reality in the field of diagnostics and offered insight into what products will win in the space.

Source: MDDI Online
769
January 23, 2018

diagnostics healthcare technologies and innovations medical device Researches

Digital currency-based fitness app Sweatcoin lands $5.7M in funding

Earning a little extra toward workout products and fitness classes could be as easy as tracking the steps you take outside. London-based Sweatcoin, a company which “pays” users a digital currency based on their daily steps, has just landed $5.7 million in a funding round led by Goodwater Capital with participation from Seedcamp, Greylock Partners, Rubylight, SmartHub, and several angel investors.

Source: Mobile Health News
646
January 23, 2018

blockchain Company Insight digital health mHealth

Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.

Source: Prnewswire
764
January 22, 2018

biopharmaceutical EP4 antagonist Market Views

Functionality, usability cited as barriers to adoption of caregiver digital health tools in AARP report

In 2014, research by the AARP estimated that 40 million Americans provide unpaid care to an adult. About 68 percent of family caregivers have no paid help and by 2020, 45 million family caregivers will care for 117 million people, according to a new report on caregivers that is part of AARP’s Project Catalyst.

Source: MedCity News
588
January 22, 2018

healthcare Home medical equipment Researches

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development in recurrent Head and Neck Cancer, including Fast Track designation granted by the FDA, initiation of clinical studies in Japan, and plans to start pivotal studies, which will incorporate the evaluation of anti-cancer immune responses, in early 2018.

Source: Prnewswire
740
January 19, 2018

anti-cancer immune New Approvals RM-1929

Leaf Healthcare touts reduced pressure injuries in Leaf wearable sensor study

Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars

Merck KGaA taps UK cancer research organizations to feed pipeline

Biosimilar Avastin wins EU approval

GSK, Pfizer lead in new global Twitter pharma influencer ranking

Diagnostic Products of the Future

Digital currency-based fitness app Sweatcoin lands $5.7M in funding

Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Functionality, usability cited as barriers to adoption of caregiver digital health tools in AARP report

Aspyrian Therapeutics Inc. announces successful advances in RM-1929 clinical development

Trending Topics

Hot Tags

Subscribe

more

more

Customer Services

About Us

Buy on Drugdu.com

Sell on Drugdu.com

Blogroll

Free APP

Follow Us